Market reactionShares fell 12% on Nov 5.
Anavex Life Sciences is a clinical-stage company developing blarcamesine (ANAVEX 2-73), an oral drug for early Alzheimer's disease, Rett syndrome and Fragile X syndrome; it is not approved.
Anavex is rebuilding blarcamesine's U.S. development path across Alzheimer's, Rett and Fragile X. Alzheimer's Phase 3 design awaits FDA alignment; adult Rett start-up continues, with a November pediatric meeting. Fragile X has an open IND for a planned adult-male Phase 2a. ADME and DDI clinical conduct is complete; analyses continue. Kellmeyer's permanent appointment supports continuity after strategy-related director departures. Cash was $118.3 million at June 30, 2026; management expects funding into mid to late fiscal 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA agrees a U.S. Phase 3 design in Alzheimer's disease
Can Anavex secure an FDA-aligned, financially feasible Phase 3 design for early Alzheimer's disease?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Permanent CEO supports continuity; Alzheimer's Phase 3 design remains central
Director resignations add strategy uncertainty as Alzheimer's Phase 3 design remains central
Blarcamesine's EU withdrawal and FDA data request define a binary: can existing Phase 2b/3 data support a U.S. NDA, or has regulatory viability collapsed entirely?
EU marketing authorization application withdrawal for blarcamesine
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain, Psychiatric disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
15 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.